SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending as investors gear up for the upcoming Goliath mainnet launch, with the community actively debating whether current price action signals a genuine breakout or another typical sell-the-news event. The conversation is heavily focused on long-term accumulation and the potential for real-world payment infrastructure, despite persistent skepticism regarding the project's historical price volatility and anonymous team details.

Cracker Barrel Old Country Store, Inc. engages in the operation and development of restaurant and retail outlets. The format of its stores consists of a trademarked rustic old country-store design that offers restaurant menu featuring home-style country food. The company was founded by Dan W. Evins on September 19, 1969 and is headquartered in Lebanon, TN.

Cracker Barrel Old Country Store Inc

Cracker Barrel is facing intense downward pressure driven by a combination of weak financial performance, disappointing guidance, and ongoing shareholder frustration regarding executive leadership and failed rebranding efforts. While some investors argue the stock's significant decline and tangible real estate assets present a long-term value opportunity, the community remains deeply divided, with many actively calling for a leadership overhaul as short interest continues to climb.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders debate its role in the emerging AI-driven identity verification sector, often drawing comparisons to OpenAI's development and broader market momentum. Investors are actively watching for treasury-related catalysts and institutional accumulation, though sentiment remains split between long-term bullish expectations for digital identity and skepticism regarding tokenomics and volatility.

Utopia is a digital paradise designed to reward every step of a user's journey. It is a world where community and cutting-edge technology converge to foster unprecedented freedom, creativity, and tangible value.At the heart of Utopia lies a living, breathing ecosystem where user engagement directly fuels the economy.Participants guide the Utopia girl on her path, drawing her closer to the world's core. With each step, a user's influence grows, as do their potential BNB rewards. Utopia is built on the principle that exploration and active participation should be directly linked to prosperity.The path is for each user to shape, and every discovery brings them closer to the center of it all.

Utopia

Utopia is gaining traction following the announcement of new ecosystem ambassadors, expanded utility through the uDegen platform, and ongoing token burns designed to strengthen its deflationary model. Community members are highly active, frequently discussing the project's long-term growth initiatives, new wallet integrations, and potential market momentum.

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals is experiencing heightened market attention and volatility driven by investor speculation over a potential buyout by major pharmaceutical players as the company continues to execute on its commercial launch and clinical pipeline. Community sentiment is deeply divided between long-term holders optimistic about the transformative potential of setmelanotide in rare obesity disorders and short-term traders reacting to insider selling activity and the company's path to profitability.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is facing intense community scrutiny as holders navigate a prolonged price decline, with the primary catalyst for current discussion being the long-awaited 'Clarity Act' and its potential to classify the token as a digital commodity. Investors remain polarized, with many expressing frustration over the lack of official corporate communication, while others continue to defend the project's long-term utility as a collateralized payment rail despite recent downward price action.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom is currently facing significant downward pressure and intense community scrutiny as investors grapple with multiple class-action lawsuits, regulatory recalls, and concerns regarding product reliability. While some traders attempt to bottom-fish the stock as it hits new lows, sentiment remains deeply polarized between those betting on a recovery and others bracing for further declines amid persistent volatility and negative sentiment from competing tech investors.

ARK Investment Management LLC - ARK Innovation ETF

ARK Innovation ETF

ARK Innovation ETF is trending as Cathie Wood aggressively accumulates shares of crypto-linked and AI-adjacent stocks, fueling active debates among the community about her high-conviction strategy and the fund's long-term viability. Investors remain split between those viewing these entries as bargain opportunities in disruptive tech and those criticizing the firm's role in the fund's historical drawdowns.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is currently driving market excitement as investors look toward the upcoming supply-halving event in December and the recent Grayscale ETF filing. The community is heavily focused on the project's decentralized AI infrastructure, with many participants actively discussing subnet staking strategies and positioning the token as a primary long-term play within the AI-crypto sector.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as the community scrutinizes the company's strategic exclusion from China's national drug list and anticipates a critical U.S. Supreme Court decision regarding patent infringement. Investors are focused on the company's improved cash position and ongoing restructuring efforts while debating the likelihood of a strategic acquisition in the cardiovascular sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7%

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling...

Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL

Portolan Capital Management LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 14.7% during the third quarter, according to the company in its most recent Form 13F...

Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00

Citigroup cut their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday...

Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group

Canaccord Genuity Group reissued a "buy" rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday...

Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS

Candel Therapeutics (NASDAQ:CADL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus...

Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research

Zacks Research upgraded Candel Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday...

Candel Therapeutics (CADL) Projected to Post Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul Manning bought 550,458 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was bought at an...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat...

Why Is Candel Therapeutics Stock Falling Friday?

Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therapies and development costs.read more...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADLCandel Therapeutics Inc